

Audit Review Table						
UnitedHealthcare Community Plan, Inc - New Mexico (Org ID: 12829, SubID: 10138, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2014						
The Auditor lock has been applied to this submission.						
Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y		N	74.45%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)	Y		N			
<i>BMI Percentile</i>				43.80%	R	Reportable
<i>Counseling for Nutrition</i>				49.39%	R	Reportable
<i>Counseling for Physical Activity</i>				35.04%	R	Reportable
Childhood Immunization Status (cis)	Y		N			
<i>DTaP</i>				65.71%	R	Reportable
<i>IPV</i>				74.29%	R	Reportable
<i>MMR</i>				80.00%	R	Reportable
<i>HiB</i>				75.71%	R	Reportable
<i>Hepatitis B</i>				74.29%	R	Reportable
<i>VZV</i>				80.00%	R	Reportable
<i>Pneumococcal Conjugate</i>				67.14%	R	Reportable
<i>Hepatitis A</i>				75.71%	R	Reportable
<i>Rotavirus</i>				64.29%	R	Reportable
<i>Influenza</i>				41.43%	R	Reportable
<i>Combination #2</i>				60.00%	R	Reportable
<i>Combination #3</i>				58.57%	R	Reportable
<i>Combination #4</i>				55.71%	R	Reportable
<i>Combination #5</i>				51.43%	R	Reportable
<i>Combination #6</i>				31.43%	R	Reportable
<i>Combination #7</i>				48.57%	R	Reportable
<i>Combination #8</i>				31.43%	R	Reportable
<i>Combination #9</i>				25.71%	R	Reportable
<i>Combination #10</i>				25.71%	R	Reportable
Immunizations for Adolescents (ima)	Y		N			
<i>Meningococcal</i>				33.33%	R	Reportable

<i>Tdap/Td</i>				53.33%	R	Reportable
<i>Combination #1</i>				33.33%	R	Reportable
Human Papillomavirus Vaccine for Female Adolescents (hvp)	N			NR	NR	Measure Unselected
Lead Screening in Children (lsc)	Y		N	25.71%	R	Reportable
Breast Cancer Screening (bcs)	Y			36.70%	R	Reportable
Cervical Cancer Screening (ccs)	Y			27.25%	R	Reportable
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)	N			NR	NR	Measure Unselected
Chlamydia Screening in Women (chl)	Y					
<i>16-20 Years</i>				47.08%	R	Reportable
<i>21-24 Years</i>				52.24%	R	Reportable
<i>Total</i>				50.28%	R	Reportable
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		59.78%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	Y		88.56%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		48.47%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			21.60%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
<i>Systemic Corticosteroid</i>				32.80%	R	Reportable
<i>Bronchodilator</i>				41.60%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
<i>5-11 Years</i>				NA	R	Denominator fewer than 30
<i>12-18 Years</i>				NA	R	Denominator fewer than 30
<i>19-50 Years</i>				60.00%	R	Reportable
<i>51-64 Years</i>				69.77%	R	Reportable

<i>Total</i>				65.17%	R	Reportable
Medication Management for People With Asthma (mma)	Y	Y				
<i>5-11 Years - Medication Compliance 50%</i>				NA	R	Denominator fewer than 30
<i>5-11 Years - Medication Compliance 75%</i>				NA	R	Denominator fewer than 30
<i>12-18 Years - Medication Compliance 50%</i>				NA	R	Denominator fewer than 30
<i>12-18 Years - Medication Compliance 75%</i>				NA	R	Denominator fewer than 30
<i>19-50 Years - Medication Compliance 50%</i>				NA	R	Denominator fewer than 30
<i>19-50 Years - Medication Compliance 75%</i>				NA	R	Denominator fewer than 30
<i>51-64 Years - Medication Compliance 50%</i>				63.33%	R	Reportable
<i>51-64 Years - Medication Compliance 75%</i>				40.00%	R	Reportable
<i>Total - Medication Compliance 50%</i>				67.24%	R	Reportable
<i>Total - Medication Compliance 75%</i>				48.28%	R	Reportable
Asthma Medication Ratio (amr)	Y	Y				
<i>5-11 Years</i>				NA	R	Denominator fewer than 30
<i>12-18 Years</i>				NA	R	Denominator fewer than 30
<i>19-50 Years</i>				46.67%	R	Reportable
<i>51-64 Years</i>				51.22%	R	Reportable
<i>Total</i>				49.43%	R	Reportable
Effectiveness of Care: Cardiovascular Conditions						
Controlling High Blood Pressure (cbp)	Y			53.04%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	N	N		NR	NR	Measure Unselected
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y		N			
<i>Hemoglobin A1c (HbA1c) Testing</i>				84.43%	R	Reportable
<i>HbA1c Poor Control (>9.0%)</i>				49.15%	R	Reportable
<i>HbA1c Control (<8.0%)</i>				43.31%	R	Reportable
<i>HbA1c Control (<7.0%)</i>				NR	NR	Plan chose not to report
<i>Eye Exam (Retinal) Performed</i>				65.21%	R	Reportable
<i>Medical Attention for Nephropathy</i>				83.70%	R	Reportable
<i>Blood Pressure Control (<140/90 mm Hg)</i>				54.74%	R	Reportable
Effectiveness of Care: Musculoskeletal Conditions						

Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		46.90%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Y			70.09%	R	Reportable
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	Y				
<i>Effective Acute Phase Treatment</i>				62.50%	R	Reportable
<i>Effective Continuation Phase Treatment</i>				48.34%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
<i>Initiation Phase</i>				NA	R	Denominator fewer than 30
<i>Continuation and Maintenance (C&M) Phase</i>				NA	R	Denominator fewer than 30
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	Y				
<i>30-Day Follow-Up</i>				71.00%	R	Reportable
<i>7-Day Follow-Up</i>				55.16%	R	Reportable
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y		74.24%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			49.76%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			NA	R	Denominator fewer than 30
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y		61.09%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	N	N				
<i>1-5 Years</i>				NR	NR	Measure Unselected
<i>6-11 Years</i>				NR	NR	Measure Unselected
<i>12-17 Years</i>				NR	NR	Measure Unselected

<i>Total</i>				NR	NR	Measure Unselected
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	N	N				
<i>1-5 Years</i>				NR	NR	Measure Unselected
<i>6-11 Years</i>				NR	NR	Measure Unselected
<i>12-17 Years</i>				NR	NR	Measure Unselected
<i>Total</i>				NR	NR	Measure Unselected
Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
<i>ACE Inhibitors or ARBs</i>				84.69%	R	Reportable
<i>Digoxin</i>				NA	R	Denominator fewer than 30
<i>Diuretics</i>				86.45%	R	Reportable
<i>Total</i>				85.29%	R	Reportable
Access/Availability of Care						
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
<i>20-44 Years</i>				78.73%	R	Reportable
<i>45-64 Years</i>				90.85%	R	Reportable
<i>65+ Years</i>				96.30%	R	Reportable
<i>Total</i>				87.21%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
<i>12-24 Months</i>				88.22%	R	Reportable
<i>25 Months - 6 Years</i>				78.24%	R	Reportable
<i>7-11 Years</i>				NA	R	Denominator fewer than 30
<i>12-19 Years</i>				NA	R	Denominator fewer than 30
Annual Dental Visit (adv)	Y	Y				
<i>2-3 Years</i>				36.45%	R	Reportable
<i>4-6 Years</i>				51.31%	R	Reportable
<i>7-10 Years</i>				54.82%	R	Reportable
<i>11-14 Years</i>				48.77%	R	Reportable
<i>15-18 Years</i>				39.86%	R	Reportable

19-21 Years				25.88%	R	Reportable
Total				41.52%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	N	N				
Initiation of AOD Treatment: 13-17 Years				NR	NR	Measure Unselected
Engagement of AOD Treatment: 13-17 Years				NR	NR	Measure Unselected
Initiation of AOD Treatment: 18+ Years				NR	NR	Measure Unselected
Engagement of AOD Treatment: 18+ Years				NR	NR	Measure Unselected
Initiation of AOD Treatment: Total				NR	NR	Measure Unselected
Engagement of AOD Treatment: Total				NR	NR	Measure Unselected
Prenatal and Postpartum Care (ppc)	Y					
Timeliness of Prenatal Care				63.75%	R	Reportable
Postpartum Care				48.18%	R	Reportable
Call Answer Timeliness (cat)	Y			92.94%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	N	N				
1-5 Years				NR	NR	Measure Unselected
6-11 Years				NR	NR	Measure Unselected
12-17 Years				NR	NR	Measure Unselected
Total				NR	NR	Measure Unselected
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y					
<21 Percent				20.68%	R	Reportable
21-40 Percent				12.17%	R	Reportable
41-60 Percent				11.19%	R	Reportable
61-80 Percent				13.38%	R	Reportable
81+ Percent				42.58%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)	N		N			
0 Visits				NR	NR	Measure Unselected
1 Visit				NR	NR	Measure Unselected
2 Visits				NR	NR	Measure Unselected
3 Visits				NR	NR	Measure Unselected
4 Visits				NR	NR	Measure Unselected
5 Visits				NR	NR	Measure Unselected

	6+ Visits				NR	NR	Measure Unselected
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y		N		65.94%	R	Reportable
Adolescent Well-Care Visits (awc)	Y		N		31.14%	R	Reportable
Frequency of Selected Procedures (fsp)	N					NR	Measure Unselected
Ambulatory Care: Total (amba)	Y					R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	N					NR	Measure Unselected
Ambulatory Care: Disabled (ambc)	N					NR	Measure Unselected
Ambulatory Care: Other (ambd)	N					NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)	Y					R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)	N					NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)	N					NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)	N					NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Total (iada)	N	N				NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N	N				NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N	N				NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Other (iadd)	N	N				NR	Measure Unselected
Mental Health Utilization: Total (mpta)	Y	Y				R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	N	N				NR	Measure Unselected
Mental Health Utilization: Disabled (mptc)	N	N				NR	Measure Unselected
Mental Health Utilization: Other (mptd)	N	N				NR	Measure Unselected
Antibiotic Utilization: Total (abxa)	N	N				NR	Measure Unselected
Antibiotic Utilization: Dual Eligibles (abxb)	N	N				NR	Measure Unselected
Antibiotic Utilization: Disabled (abxc)	N	N				NR	Measure Unselected
Antibiotic Utilization: Other (abxd)	N	N				NR	Measure Unselected

Relative Resource Use						
Relative Resource Use for People With Diabetes (rdi)	N				NR	Measure Unselected
Relative Resource Use for People With Asthma (ras)	N	N			NR	Measure Unselected
Relative Resource Use for People With Cardiovascular Conditions (rca)	N				NR	Measure Unselected
Relative Resource Use for People With Hypertension (rhy)	N				NR	Measure Unselected
Relative Resource Use for People With COPD (rco)	N				NR	Measure Unselected
Health Plan Descriptive Information						
Board Certification (bcr)	Y				R	Reportable
Total Membership (tlm)	Y				R	Reportable
Enrollment by Product Line: Total (enpa)	Y				R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	N				NR	Measure Unselected
Enrollment by Product Line: Disabled (enpc)	N				NR	Measure Unselected
Enrollment by Product Line: Other (enpd)	N				NR	Measure Unselected
Enrollment by State (ebs)	Y				R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	N				NR	Measure Unselected
Language Diversity of Membership (ldm)	N				NR	Measure Unselected
Weeks of Pregnancy at Time of Enrollment (wop)	N				NR	Measure Unselected